Having trouble accessing articles? Reset your cache.

Amonafide L-malate: Development discontinued

Antisoma discontinued development of amonafide after data from the open-label, international Phase III ACCEDE trial in over 420 patients showed that 600 mg/m 2 IV amonafide for 5 days plus cytarabine missed the primary endpoint of

Read the full 368 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers